Their study showed a 9% editing efficiency, indicating the potential for FH gene therapy [16]. FJ Real et al. thought that Evinacumab, an anti-ANGPTL3 monoclonal antibody, could treat people with homozygous FH. Numerous studies have demonstrated that Evinacumab can significantly lower LDL ...
Methods: A comprehensive review was conducted of the literature on the diagnosis of FH, the morbidity and mortality related to treated and untreated FH, and the evidence on the effectiveness of treatment of FH in adults and children. Treatment options have changed since statin treatment became ...
The guidelines for the diagnosis and treatment of novel coronavirus pneumonia (the seventh edition) issued by the National Health Commission and the State Administration of TCM of the People’s Republic of China recommends the use of certain antiviral drugs, but not the anti-COVID-19 indications,...
YOLT-101, developed independently by YolTech, aims to intervene in specific genetic mutations associated with Familial Hypercholesterolemia. Leveraging advanced gene editing technology and lipid nanoparticle (LNP) delivery, YOLT-101 prom...
Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, American Heart Association; American Diabetes Association: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circu...
The processing is used for purposes such as to integrate content, external services and elements from third parties, statistical analysis/measurement, personalized advertising and the integration of social media. Depending on the function, data is passed on to up to 123 third parties and processed ...
Combination therapy with different classes of antihypertensive drugs exhibits potent hypotensive effects, and is useful for achieving the target of blood pressure control (Recommendation grade: A, Evidence level: I). 8 Among the combinations of two drugs, those of a renin–angiotensin (RA) system...
The current and future therapeutic options targeting residual CVD risk have been summarized in a multidisciplinary manner. Familial hypercholesterolemia (FH) is a fairly common hereditary lipid disorder that is characterized by a marked increase in low-densitylipoprotein cholesterol (LDL-C) levels and ...
Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP:Well, there are several guidelines within the United States and internationally for the treatment of mRCC. They have a variety of options that are available, some with more evidence to support them than others. ...
The prevalence of peripheral arterial disease is rapidly increasing, and currently affects 8 to 12 million people in the United States [3]. Patients with CLI often have poor prognosis, leading to amputation of the lower extremities [1]. Several alternative approaches are currently under ...